Abcam, ab305115, Alexa Fluor® 488 Anti-CGRP-I+CGRP-II antibody [EPR23804-95]

Size: 100µL
Rabbit Recombinant Monoclonal CGRP-I antibody - conjugated to Alexa Fluor® 488. Suitable for IHC-P, ICC/IF and reacts with Mouse, Rat, Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23804-95,
Isotype:IgG,
Conjugation:Alexa Fluor® 488,
Excitation/Emission:Ex: 495nm, Em: 519nm,
Carrier free:No,
Reacts with:Human, Mouse, Rat,
Applications:ICC/IF, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The target designated as CGRP-I and CGRP-II refers to calcitonin gene-related peptide isoforms which play key roles in various physiological functions. CGRP around 37 amino acids long has alternative names such as alpha-CGRP and beta-CGRP occurring mainly in the central nervous system and peripheral nervous tissues. These peptides are potent vasodilators integral to the modulation of blood vessel tone and immune responses. Both isoforms though small in mass allow for significant physiological impacts due to their receptor interactions.
Biological function summary
CGRP-I and CGRP-II contribute to vasodilation and pain transmission in the nervous system. Each isoform can activate specific CGRP receptors mainly located on smooth muscle cells and neurons without forming stable complexes. Their activity involves increasing intracellular cAMP levels facilitating vascular relaxation and modulating nociceptive pathways. Consequently CGRP peptides are essential for conveying pain signals and supporting neurogenic inflammation mechanisms.
Pathways
CGRP-I and CGRP-II serve critical roles in the cardiovascular and nervous system pathways. The cAMP-dependent pathway one of the essential routes of action elevates vasodilation responses where CGRP interacts with the RAMP1 protein a receptor accessory protein. Another pathway involves the modulation of pain where CGRP interacts with other neurotransmitters and proteins such as substance P and neurokinin.
CGRP-I and CGRP-II show significant associations with migraines and hypertension. These peptides through their vasodilatory capabilities and nociceptive signaling connect to migraines by interacting with proteins like RAMP1 in trigeminal neurons exacerbating migraine pathology. Furthermore CGRP's role in promoting vasodilation links to hypertension management where altered CGRP activity affects blood pressure regulation. These connections make CGRP-related pathways viable targets for therapeutic intervention.